Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Under the first phase of the ongoing two part study, the drug demonstrated "statistically significant improvement in liver fibrosis and resolution of steatohepatitis compared to placebo." In August 2025, the company received final approval to market the therapy for the additional indication in the US, followed by a conditional approval in Canada in December
After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025
[Accessed 29 Aug 2023] Eli Lilly and Company 2023
Watch our video to learn how DPP-4 complicates measuring GLP-1 accurately
Clinical trials evaluating semaglutide have primarily focused on glycaemic control, cardiovascular outcomes, and weight reduction, with adverse event monitoring centred on gastrointestinal tolerability, hypoglycaemia risk, and complications such as pancreatitis or diabetic retinopathy progression
Tirzepatide is available as Mounjaro (diabetes indication), Zepbound (weight management indication), and compounded tirzepatide
US$ 22.50
US$ 20.87
US$ 25.27
US$ 25.64
US$ 22.93
US$ 28.49
US$ 24.69
US$ 24.45
